Skip to content

Gilead Sciences GILD Share Buybacks

Share Buybacks at other companies

AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$0-100%
Merck & Co. logo
Merck & Co.MRK
$874M-24.9%

Other financials

Income statement

See full
Revenue$7.0B+4.4%
Gross profit$5.5B+7.6%
Operating income$2.6B+15.6%
Net income$2.0B+53.7%
EPS (diluted)$1.61+54.8%

Balance sheet

See full
Cash & equivalents$7.6B-3.8%
Total debt$22.2B-11.1%
Total equity$23.5B+22.7%
Total assets$56.3B-0.3%

Cash flow

See full
Operating cash flow$2.5B+44.8%
CapEx$117.0M+12.5%
Free cash flow$2.4B+46.8%

Valuation

See full
Market cap$167.41B+20.4%
Enterprise value$181.96B+14.5%
P/E18.2×-3.9×
P/S5.6×+0.8×

Profitability

See full
Gross margin79.4%+1.1pp
Operating margin34.9%+6.3pp
Net margin31%+10.2pp
FCF margin34.4%+0.1pp

Returns & leverage

See full
Return on equity43.2%+10.7pp
Debt / equity0.9×-0.4×
Current ratio+0.6×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gilead Sciences's share buybacks.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gilead Sciences's share buybacks?
Gilead Sciences (GILD) reported share buybacks of $419M in Q1 2026.
How has Gilead Sciences's share buybacks changed year-over-year?
Gilead Sciences's share buybacks decreased by 42.6% year-over-year, from $730M to $419M.
What is the long-term trend for Gilead Sciences's share buybacks?
Over 4 years (2021 to 2025), Gilead Sciences's share buybacks has grown at a 37.0% compound annual growth rate (CAGR), from $546M to $1.92B.
What does share buybacks mean?
Cash used to buy back the company's own shares on the open market or through structured programs, reducing shares outstanding.